drugset / Trial / NCT03744949

ED50 and ED95 of Remifentanil for Intubation Without NOL Variation

NCT03744949

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Our aim, in this study, is to elucidate the optimal dosing range (ED50 and ED95) of bolus remifentanil in order to counter the painful stimuli resulting from direct laryngoscopy and tracheal intubation by using the NOL index. In order to maximize the clinical relevance of our findings, induction of general anesthesia will be done with standard medications and doses and laryngoscopy will be done with the Macintosh laryngoscope, the most common tool used for intubation in the operating room

Timeline

Start
2018-03-14
Primary completion
2018-10-19
Completion
2021-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Remifentanil Small molecule 0.5 ug/kg
Subject Remifentanil Small molecule 1 ug/kg
Subject Remifentanil Small molecule 1.5 ug/kg
Subject Remifentanil Small molecule 2 ug/kg

Indications

No indication recorded.